GlassScriptPhysician profile
Colin D Shafer
NPI 1306810494
$3,815.66
in general payments reported to CMS, 2019-2025
19 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $217 · 2021: $258 · 2022: $687 · 2023: $590 · 2024: $489 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $845.02 | 2022-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $573.11 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Corevalve Evolut R, Micra |
| Boston Scientific Corporation | $512.40 | 2019-2025 | Watchman Access System, General - Ep, Watchman Flx |
| Abbott Laboratories | $487.02 | 2021-2025 | Portico, Amplatzer Amulet, Triclip |
| Lantheus Medical Imaging, INC. | $312.91 | 2019-2025 | Definity |
| Medtronic Vascular, INC. | $225.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $216.64 | 2019-2023 | Wainua |
| Alnylam Pharmaceuticals INC. | $108.22 | 2019-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $102.07 | 2019-2020 | |
| Pfizer INC. | $87.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $75.08 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.35 | 2020-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $53.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.58 | 2019 | |
| Irhythm Technologies, INC. | $24.04 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.03 | 2025 | Jardiance |
| Lundbeck LLC | $21.25 | 2019 | |
| Amarin Pharma, INC. | $17.85 | 2020 | |
| Atricure, INC. | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Shafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.